Inhibition of Ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity

Cancer Discovery

Volumn 3, Issue 7, 2013, Pages 751-760

  Eyob, Henok ^a   Ekiz, Huseyin Atakan ^a   DeRose, Yoko S ^a   Waltz, Susan E ^c   Williams, Matthew A ^b   Welm, Alana L ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASLAN 002; BMS 777607; IMMUNOGLOBULIN G; INTERLEUKIN 12; PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RON KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; LYMPHOCYTE; MICROMETASTASIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY; MICE; NEOPLASM MICROMETASTASIS; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84880320233     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0480     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011; 108: 12396-400.
3. Teng MWL, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008; 84: 988-93.
4. Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494: 361-5.
5. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-46.
6. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-7.
7. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10: 871-7.
8. Teng MWL, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012; 72: 3987-96.
9. Eyles J, Puaux A-L, Wang X, Toh B, Prakash C, Hong M, et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120: 2030-9.
10. Trapani JA, Smyth MJ. Functional significance of the perforin/ granzyme cell death pathway. Nat Rev Immunol 2002; 2: 735-47.
11. Calzascia T, Pellegrini M, Hall H, Sabbagh L, Ono N, Elford AR, et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007; 117: 3833-45.
12. + T cells. J Immunol 2008; 181: 6148-57.
13. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
14. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, van de Vijver MJ, Hasegawa BH, et al. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 2007; 104: 7570-5.
15. Kretschmann KL, Eyob H, Buys SS, Welm AL. The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets 2010; 11: 1157-68.
16. Bhatt AS, Welm A, Farady CJ, Vásquez M, Wilson K, Craik CS. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A 2007; 104: 5771-6.
17. Kawaguchi M, Orikawa H, Baba T, Fukushima T, Kataoka H. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein. FEBS J 2009; 276: 3481-90.
18. Kurihara N, Tatsumi J, Arai F, Iwama A, Suda T. Macrophagestimulating protein (MSP) and its receptor, RON, stimulate human osteoclast activity but not proliferation: effect of MSP distinct from that of hepatocyte growth factor. Exp Hematol 1998; 26: 1080-5.
19. Suzuki Y, Funakoshi H, Machide M, Matsumoto K, Nakamura T. Regulation of cell migration and cytokine production by HGF-like protein (HLP)/macrophage stimulating protein (MSP) in primary microglia. Biomed Res 2008; 29: 77-84.
20. Liu Q-P, Fruit K, Ward J, Correll PH. Negative regulation of macrophage activation in response to IFN-γ and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol 1999; 163: 6606-13.
21. Waltz SE, Eaton L, Toney-Earley K, Hess KA, Peace BE, Ihlendorf JR, et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 2001; 108: 567-76.
22. Morrison AC, Correll PH. Activation of the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase by macrophage-stimulating protein results in the induction of arginase activity in murine peritoneal macrophages. J Immunol 2002; 168: 853-60.
23. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/ RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol 2004; 172: 1825-32.
24. Wilson CB, Ray M, Lutz M, Sharda D, Xu J, Hankey PA. T he RON receptor tyrosine kinase regulates IFN-gamma production and responses in innate immunity. J Immunol 2008; 181: 2303-10.
25. Sharda DR, Yu S, Ray M, Squadrito ML, De Palma M, Wynn TA, et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol 2011; 187: 2181-92.
26. Wang MH, Skeel A, Leonard EJ. Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases. J Clin Invest 1996; 97: 720-7.
27. Nanney LB, Skeel A, Luan J, Polis S, Richmond A, Wang MH, et al. Proteolytic cleavage and activation of pro-macrophage-stimulating protein and upregulation of its receptor in tissue injury. J Invest Dermatol 1998; 111: 573-81.
28. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
29. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009; 4: e6562.
30. Huang P, Duda DG, Jain RK, Fukumura D. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med 2008; 58: 253-63.
31. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2: 251-62.
32. Schroeder GM, An Y, Cai Z-W, Chen X-T, Clark C, Cornelius L AM, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009; 52: 1251-4.
33. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-4.
34. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-66.
35. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-46.
36. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
37. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
38. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-73.
39. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004; 64: 7022-9.
40. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1: 54-67.
41. Lepique AP, Daghastanli KRP, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin Cancer Res 2009; 15: 4391-400.
42. Gurusamy D, Gray JK, Pathrose P, Kulkarni RM, Finkleman FD, Waltz SE. Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. Cancer Res 2013; 73: 1752-63.
43. Lentsch AB, Pathrose P, Kader S, Kuboki S, Collins MH, Waltz SE. The Ron receptor tyrosine kinase regulates acute lung injury and suppresses nuclear factor kappaB activation. Shock 2007; 27: 274-80.
44. McDowell SA, Mallakin A, Bachurski CJ, Toney-Earley K, Prows DR, Bruno T, et al. The role of the receptor tyrosine kinase Ron in nickel-induced acute lung injury. Am J Respir Cell Mol Biol 2002; 26: 99-104.
45. + T cells expressing IL-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010; 70: 6725-34.
46. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006; 17: 750-62.
47. Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H, et al. Blockade of programmed death-1 pathway rescues the effector function of tumorinfiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol 2010; 185: 5082-92.
48. Spangrude GJ, Brooks DM, Tumas DB. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood 1995; 85: 1006-16.
49. Cruz-Guilloty F, Pipkin ME, Djuretic IM, Levanon D, Lotem J, Lichtenheld MG, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 2009; 206: 51-9.
50. Jaskelioff M, Song W, Xia J, Liu C, Kramer J, Koido S, et al. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene 2009; 28: 4225-36.
51. Wu CA, Peluso JJ, Shanley JD, Puddington L, Thrall RS. Murine cytomegalovirus influences foxj1 expression, ciliogenesis, and mucus plugging in mice with allergic airway disease. Am J Pathol 2008; 172: 714-24.